Skip to main content
Journal cover image

High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.

Publication ,  Journal Article
Botty van den Bruele, A; Ren, Y; Thomas, SM; Ntowe, KW; Rosenberger, LH; Menendez, C; Grimm, LJ; Chiba, A; Plichta, JK
Published in: Breast Cancer Res Treat
June 2025

BACKGROUND: The risk of developing breast cancer up to age 80 for women with BRCA1/2 mutations is approximately 69-72%. The risk estimates, however, become labile in the later years of life. Many older BRCA1/2 mutation carriers who have not developed breast cancer continue to undergo high-risk surveillance. We evaluated breast cancers in women age ≥ 70 and identified which modality diagnosed the malignancy. METHODS: Females with BRCA1/2 mutations identified between 1996 and 2022 were included in this single institution retrospective review. The cohort was divided by age at BRCA1/2 diagnosis (30-59, 60-69 & ≥ 70). The number of malignancies and imaging modality which led to the diagnosis were recorded. RESULTS: There were 316 patients with BRCA1/2 mutations: 266/316 (84.2%) were 30-59 years old at the time of genetic testing, 35/316 (11.1%) were 60-69, and 15/316 (4.7%) were ≥ 70. Median follow-up was 57 months (IQR 21.6-114.6). There were 178 (56.3%) breast malignancies diagnosed; 161/266 (60.5%) age 30-59, 11/35 (31.4%) ages 60-69, and 6/15 (40%) age ≥ 70 (p = 0.002). Of patients with a malignant diagnosis (n = 178), 140/178 (78.7%) had their cancers discovered on either screening or diagnostic mammogram, 30/178 (16.9%) by MRI, 1 /178 (0.6%) on ultrasound, and 1/178 (0.6%) was discovered on surgical pathology. Of the breast cancers diagnosed in patients age ≥ 70, 66.7% (4/6) were found on mammogram. CONCLUSIONS: In women ≥ 70 with BRCA1/2 mutations, mammograms may be sufficient surveillance. Given that a number of older BRCA1/2 carriers may never develop breast cancer, our data supports individualized care and consideration for de-escalated surveillance in those ≥ 70.

Duke Scholars

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

June 2025

Volume

211

Issue

2

Start / End Page

421 / 429

Location

Netherlands

Related Subject Headings

  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Mutation
  • Middle Aged
  • Mammography
  • Magnetic Resonance Imaging
  • Humans
  • Heterozygote
  • Genetic Testing
  • Genetic Predisposition to Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Botty van den Bruele, A., Ren, Y., Thomas, S. M., Ntowe, K. W., Rosenberger, L. H., Menendez, C., … Plichta, J. K. (2025). High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old. Breast Cancer Res Treat, 211(2), 421–429. https://doi.org/10.1007/s10549-025-07657-y
Botty van den Bruele, Astrid, Yi Ren, Samantha M. Thomas, Koumani W. Ntowe, Laura H. Rosenberger, Carolyn Menendez, Lars J. Grimm, Akiko Chiba, and Jennifer K. Plichta. “High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.Breast Cancer Res Treat 211, no. 2 (June 2025): 421–29. https://doi.org/10.1007/s10549-025-07657-y.
Botty van den Bruele A, Ren Y, Thomas SM, Ntowe KW, Rosenberger LH, Menendez C, et al. High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old. Breast Cancer Res Treat. 2025 Jun;211(2):421–9.
Botty van den Bruele, Astrid, et al. “High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old.Breast Cancer Res Treat, vol. 211, no. 2, June 2025, pp. 421–29. Pubmed, doi:10.1007/s10549-025-07657-y.
Botty van den Bruele A, Ren Y, Thomas SM, Ntowe KW, Rosenberger LH, Menendez C, Grimm LJ, Chiba A, Plichta JK. High risk surveillance MRI may not be necessary in BRCA1/2 mutation carriers over 70 years old. Breast Cancer Res Treat. 2025 Jun;211(2):421–429.
Journal cover image

Published In

Breast Cancer Res Treat

DOI

EISSN

1573-7217

Publication Date

June 2025

Volume

211

Issue

2

Start / End Page

421 / 429

Location

Netherlands

Related Subject Headings

  • Retrospective Studies
  • Oncology & Carcinogenesis
  • Mutation
  • Middle Aged
  • Mammography
  • Magnetic Resonance Imaging
  • Humans
  • Heterozygote
  • Genetic Testing
  • Genetic Predisposition to Disease